Innocoll AG (NASDAQ:INNL) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday.

According to Zacks, “Innocoll Holdings develops and manufactures pharmaceutical products and medical devices through its proprietary collagen-based technologies. The company’s product include CollaGUARD(Ex-US), CollatampG(R), Septocoll(R), RegenePro(R), Collieva(R), CollaCare(R), Collexa(R) and Zorpreva(TM). It operates primarily in Asia, Australia, Canada, Europe, Latin America, the Middle East and the United States. Innocoll AG, formerly known as Innocoll GmbH, is headquartered in Athlone, Ireland. “

Separately, FBR & Co began coverage on Innocoll AG in a research report on Thursday, June 30th. They set an “outperform” rating and a $18.00 price target on the stock.

Shares of Innocoll AG (NASDAQ:INNL) traded down 0.82% during midday trading on Tuesday, hitting $6.03. 150,859 shares of the company’s stock traded hands. Innocoll AG has a 52 week low of $4.57 and a 52 week high of $13.72. The stock’s market cap is $146.85 million. The company has a 50 day moving average of $6.03 and a 200 day moving average of $6.84.

Innocoll AG (NASDAQ:INNL) last released its earnings results on Wednesday, August 17th. The specialty pharmaceutical company reported ($0.62) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.73) by $0.11. The company earned $1.30 million during the quarter, compared to analysts’ expectations of $1.04 million. Innocoll AG had a negative return on equity of 1,226.28% and a negative net margin of 1,139.95%. On average, equities analysts forecast that Innocoll AG will post ($2.41) EPS for the current fiscal year.

Innocoll AG Company Profile

Innocoll Holdings plc is a commercial-stage specialty pharmaceutical and medical device company with late stage development programs targeting areas of significant unmet medical need. The Company utilizes its collagen-based technology platform to develop biodegradable and fully bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically.

5 Day Chart for NASDAQ:INNL

Receive News & Stock Ratings for Innocoll AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innocoll AG and related stocks with our FREE daily email newsletter.